---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-23-000023"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:51:34.866223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Schrödinger FY2022 total revenue $181M (+31%); Q4 revenue $56.8M (+23%); net loss widens to $149M

## Summary
- FY2022 total revenue $181.0M (+31% YoY); software revenue $135.6M (+20%), drug discovery $45.4M (+84%).
- Net loss $149.2M versus $101.2M in 2021; operating expenses $247.8M (+40%).
- Q4 total revenue $56.8M (+23%); software revenue $47.8M (+24%), drug discovery $9.0M (+19%).
- FY2023 guidance: software revenue growth 13-17%, drug discovery revenue $70-90M, cash burn expected to decline.
- Received ~$111.3M cash distribution from Nimbus in Feb 2023; expects ~$36M additional in Q2 2023.

## SEC filing metadata
- accession: 0001490978-23-000023
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/sdgr-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-23-000023
- JSON: https://secwatch.observer/filing/0001490978-23-000023.json
- Plain text: https://secwatch.observer/filing/0001490978-23-000023.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported Fiscal year ending December 31, 2023 results: revenue Software revenue growth expected to be in the range of 13 to 17 percent; Drug discovery revenue expected to range from $. Guidance initiated.
  - Period: Fiscal year ending December 31, 2023
  - Revenue: Software revenue growth expected to be in the range of 13 to 17 percent; Drug discovery revenue expected to range from $
  - Guidance: initiated
  - Result: guidance update
  source text: • Software revenue growth is expected to be in the range of 13 to 17 percent • Drug discovery revenue is expected to range from $70 million to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm
- Earnings Releases
  Schrodinger, Inc. reported Twelve months ended December 31, 2022 results: revenue Total revenue $181.0 million, net income Net loss $(149.2) million.
  - Period: Twelve months ended December 31, 2022
  - Revenue: Total revenue $181.0 million
  - Net income: Net loss $(149.2) million
  - Result: reported results
  source text: Total revenue for the full year increased 31% to $181.0 million, compared to $137.9 million for 2021. • Software revenue for the full year 2022 increased 20% to $135.6 million, compared to $113.2 million for 2021, with multi-year agreements making a similar contribution to reported revenue to the contribution in 2021 and 2020. • Drug discovery revenue for the full year was $45.4 million for the full year 2022, compared to $24.7 million for 2021. • Software gross margin was 78% for the full year, compared to 77% for 2021. • Operating expenses were $247.8 million for the full year, compared to $177.1 million for 2021. • Other expense, which includes gains/loss on equity investments, changes in fair value of such investments and interest income/expense, was $2.3 million for the full year, compared to other income of $10.6 million for 2021. • Net loss for the full year was $149.2 million, compared to $101.2 million for 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.